Aegera Therapeutics   Report issue

For profit Phase 2
Founded: Montreal Canada (1997)
Status: Acquired by Pharmasciences (2011) → now Ferring (2011)

Organization Overview

First Clinical Trial
2005
NCT00363974
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aegera Therapeutics, Inc | Aegera Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

aeg33773 (1 trial)

aeg35156 (7 trials)

sorafenib (nexavar) (1 trial)

xiap antisense (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Chronic Pain (Phase 2)

Diabetic Neuropathies (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Neoplasms (Phase 1)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 4